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Abstract
Aims Heart failure (HF) management is complicated by diffi-
culties in clinical assessment. Biomarkers may help guide HF
management, but the correspondence between clinical evalu-
ation and biomarker serum levels has hardly been studied. We
investigated the correlation between biomarkers and clinical
signs and symptoms, the influence of patient characteristics
and comorbidities on New York Heart Association (NYHA)
classification and the effect of using biomarkers on clinical
evaluation.
Methods and results This post-hoc analysis comprised 622
patients (77±8 years, 76 % NYHA class ≥3, 80 % LVEF
≤45 %) participating in TIME-CHF, randomising patients to
either NT-proBNP-guided or symptom-guided therapy.
Biomarker measurements and clinical evaluation were per-
formed at baseline and after 1, 3, 6, 12 and 18 months. NT-
proBNP, GDF-15, hs-TnT and to a lesser extent hs-CRP and
cystatin-C were weakly correlated to NYHA, oedema, jugular
vein distension and orthopnoea (ρ-range: 0.12–0.33; p <0.01).
NT-proBNP correlated more strongly to NYHA class in the
NT-proBNP-guided group compared with the symptom-
guided group. NYHA class was significantly influenced by
age, body mass index, anaemia, and the presence of two or
more comorbidities.
Conclusion In HF, biomarkers correlate only weakly with
clinical signs and symptoms. NYHA classification is influ-
enced by several comorbidities and patient characteristics.
Clinical judgement seems to be influenced by a clinician’s
awareness of NT-proBNP concentrations.
Keywords Heart failure . NT-proBNP . Natriuretic peptide .
Biomarkers . Cystatin-C . Hs-CRP . Hs-TnT . GDF-15
Introduction
Heart failure (HF) is a prominent health issue of the Western
civilisation affecting up to 10 % of those aged over 75 years.
Despite global consensus on treatment goals, HFmanagement
remains suboptimal, resulting in high mortality and
hospitalisation rates [1]. In part, this may be due to difficulties
in clinical evaluation, with symptoms and signs often being
vague and undiscriminating [2]. In search for more objective
clinical evaluation methods, B-type natriuretic peptide (BNP)
and N-terminal pro-BNP (NT-proBNP) were suggested as
biomarkers for assessment of the severity of HF. Measure-
ments of BNP and NT-proBNP have proven to provide sig-
nificant information regarding diagnostics and prognosis [3],
reflecting endogenous responses to cardiac overload and
neuro-hormonal stimulation [4]. Nonetheless, the sole
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measurement of natriuretic peptides may be insufficient, as
they are not specific for cardiac overload but reflect multiple
cardiac and non-cardiac pathologies [5] and are influenced by
various other factors such as body mass index (BMI) [6], age
[7], gender [8], and renal function [9]. On the other hand, HF
pathophysiology is complex, involving various pathways.
Thus, biomarkers other than natriuretic peptides such as
high-sensitivity troponin T (hsTNT) reflecting myocyte injury
[10], growth differentiation factor-15 (GDF15), associated
with cardiac hypertrophy and dilated cardiomyopathy [11],
serum cystatin C reflecting renal function [12] and high sensi-
tivity C-reactive protein (hsCRP) indicative of inflammation
[13], could be valuable in the evaluation of HF patients. Al-
though implementation of biomarkers in the clinical care of HF
has been under extensive investigation, correlations between
biomarkers and signs and symptoms of HF, though important
for further clinical implementation, remain largely unknown
and limited to New York Heart Association (NYHA) class and
natriuretic peptides [14–21]. Also, clinical assessment may not
be completely independent of knowledge on biomarkers, as
suggested for the intervention arm in studies investigating NT-
proBNP-guided treatment [22] which are usually single
blinded. Therefore, we investigated correlations between bio-
markers and signs and symptoms of HF, assessed the effect of
patient characteristics on symptoms and addressed the effect of
knowing NT-proBNP levels on clinical judgement in the Trial
of Intensified versus standard Medical therapy in Elderly pa-
tients with Congestive Heart Failure (TIME-CHF) [23].
Methods
Study design and population
Study design andmethods of TIME-CHF have been described
elsewhere [23]. In brief, TIME-CHF was a randomised, con-
trolled, single-blinded, multicentre trial conducted in 15 clin-
ical centres in Switzerland and Germany. Chronic HF patients
older than 60 years, with dyspnoea defined by NYHA class≥2
under therapy, a history of HF-related hospitalisation within
the last year before inclusion, NT-proBNP levels of≥400 ng/l
in patients aged 60–74 years and≥800 pg/ml in patients
aged≥75 years, BMI≤35 kg/m2 and serum creatinine≤
220 μmol/l were included.
A total population of 622 patients, 499 with reduced (i.e.
left-ventricular ejection fraction (LVEF) ≤45 %) and 123 with
preserved LVEF of >45 %, was included between January
2003 and December 2006. Patients were randomised to either
NT-proBNP-guided or symptom-guided management. Pa-
tients were followed up at pre-specified visits after 1, 3, 6,
12 and 18 months in the outpatient clinics of the participating
centres. NT-proBNP levels were measured in all patients at
every visit, although investigators were only provided with
results in the NT-proBNP-managed patients. Investigators
performed clinical assessment on all patients at every visit.
This included NYHA classification for assessment of dys-
pnoea and severity of oedema, rales, central venous pressure
(CVP) and orthopnoea, which were ranked between 0 and 3
(none, minor, moderate, severe).
Medical treatment was prescribed according to current
guidelines by predefined escalation rules [23]. Treatment
goals were defined as either a reduction of clinical symptoms
to NYHA≤2 or an additional reduction of NT-proBNP below
the age-specific target values≤400 ng/l for patients aged≤
75 years and≤800 ng/l for patients aged≥75 years for
symptom-guided or NTpro-BNP-guided management respec-
tively. Judgement regarding the possibility of treatment esca-
lation was left to the investigator and based on clinical status
and presence of significant side effects.
Biomarkers were measured by the use of commercially
available assays by Roche diagnostics (Elecsys 2010).
Statistical analysis
Baseline characteristics are presented as mean ± standard
deviation SD, median (interquartile range (IQR)) or frequen-
cies and percentages, as appropriate. Correlations between
NYHA class, severity of other signs and symptoms and bio-
markers were investigated using non-parametric Spearman’s
correlation (ρ). Correlations were assessed in the entire pop-
ulation and separately for the two treatment groups to assess
whether knowledge of NT-proBNP concentrations influenced
clinical judgement. To further investigate this effect, we split
patients into early- and late-included patients, i.e. included
before or after 21 January 2005, respectively, to see whether
study duration affected the influence of NT-proBNP concen-
trations on clinical judgement. Other subgroup analyses ad-
dressed the influence of age, systolic dysfunction, BMI, kid-
ney disease, chronic obstructive pulmonary disease (COPD),
stroke, peripheral artery disease, pulmonary artery hyperten-
sion, cancer and presence or absence of ≥2 comorbidities on
the correlation between NT-proBNP and clinical signs and
symptoms. Logistic regression was performed to identify
characteristics or comorbidities that influence NYHA classi-
fication at baseline. Statistically significant variables were
entered into multivariate logistic regression analysis. First,
patient characteristics were entered into the model using a
stepwise backward procedure using p <0.05 for inclusion
and p <0.1 for exclusion in the model. Then, biomarkers were
entered similarly in the model.
Differences between correlations in treatment groups and
other subgroups were investigated using the formula de-
scribed by Cohen and Cohen (1983) [24] for comparison of
independent correlation coefficients, following Fischer’s r-to-
z transformation. Other statistical calculations were performed
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Baseline characteristics are depicted in Table 1. This study
comprised a highly symptomatic (i.e. 76%NYHA ≥3) elderly
HF population, with a high prevalence of comorbidities. The
majority of patients suffered from systolic dysfunction. Of the
patients, 70 either died or were lost to follow-up at month 1,
40 at month 3, 29 at month 6, 56 at month 12, and 26 at month
18. Thus, a total of 222 (36%) did not complete the total study
period of 18 months, of whom 82 withdrew consent and 140
died.
Correlations between NT-proBNP and clinical signs
Significant though weak correlations were identified between
NT-proBNP and clinical signs and symptoms, at all visits. The
strongest correlations were identified with NYHA class and
jugular vein distention, respectively (Table 2). The correlation
between NYHA class and NT-proBNP was largely indepen-
dent of patient characteristics and comorbidities (data not
shown).
Correlations between other biomarkers and NYHA class
All biomarkers were weakly, though significantly, correlated
with NYHA class at most visits, though less than with NT-
proBNP. Correlations between NYHA and hsTNT, cystatin C
and GDF 15, respectively, were comparable. Correlations
between hsCRP and NYHAwere the weakest and not signif-
icant at all visits (Table 2).
Influence of NT-proBNP-guided therapy
Correlations between NT-proBNP and NYHA became stron-
ger in the NT-proBNP-guided compared with the symptom-
guided group as the study progressed (Fig. 1a). Interestingly,
there was no significant influence of treatment group alloca-
tion in the early-included patients (Fig. 1b), whereas the
influence of treatment group allocation on the correlation
between NT-proBNP and NYHA was most pronounced in
patients included in the second half of the study (Fig. 1c).
Correlations between oedema and NT-proBNP were stronger
in the NT-proBNP guided at the 18-month visit, whereas the
correlation between JV distention and NT-proBNP was stron-
ger in the clinically guided at the 3-month visit (Supplemental
Fig. 1 A-D). Correlations between other signs and symptoms
did not differ between the treatment groups. Correlations
between other biomarkers and NYHA classification overall
did not differ between treatment groups, besides GDF15 and
NYHA, which correlated stronger in the NT-proBNP-guided
group at the 3-month visit (Supplemental Fig. 2 A-D).
Predictors of NYHA class
Several patient characteristics such as BMI, gender and sev-
eral comorbidities were found to be related to NYHA class ≥3
(Table 3). Multivariable analysis indicated that age, female
gender, BMI, anaemia and pulmonary artery hypertension
(PAH) were associated with NYHA class ≥3 (Table 3). The
stepwise addition of biomarkers to this model showed that
Table 1 Baseline characteristics
Age, mean (SD), y 76.9±7.6
Male, n (%) 369 (59 %)
Body mass index, mean (SD) 25.6±4.44
Systolic dysfunction, n (%) 499 (80.2 %)
Primary cause of heart failure, n (%)
Coronary artery disease 330 (53.1 %)
Hypertensive heart disease 173 (27.8 %)
Dilated cardiomyopathy 89 (14.3 %)
Valvular heart disease 23 (3.7 %)
Other 7 (1.1 %)
Biomarkers
N-terminal BNP, median (IQR), ng/l 3836 (1916–6905)
HsTNT, median (IQR), pg/ml 32.5 (18.6–59.8)
Cystatin-c, median (IQR), pg/ml 1.79 (1.44–2.20)
Creatinine, mean (SD) μmol/l 116±38
HsCRP, median (IQR), pg/ml 7.7 (2.8–18.0)
Medical history, n (%)
Diabetes 222 (35.7 %)
Hypertension 462 (74.3 %)
Dilated cardiomyopathy 94 (15.1 %)
Kidney disease 355 (57.1 %)
Comorbidity (≥2) 459 (73.8 %)
Atrial fibrillation 210 (33.8 %)
COPD 124 (19.9 %)
Stroke 52 (8.4 %)
Peripheral artery disease 124 (19.9 %)
Pulmonary artery hypertension 50 (8 %)
Anaemia 175 (28.1 %)
Cancer 86 (13.8 %)
Clinical examination, n (%)
Orthopnoea (0–3) 197/225/144/53 (32/36/23/9 %)
Oedema (0–3) 357/103/93/64 (58/17/15/10 %)
Rales (0–3) 340/197/67/16 (55/32/11/2 %)
Jugular vein distention (0–3) 237/161/119/92 (39/26/20/
15 %)
NYHA (II, III, IV) 149/388/85 (24/62/14 %)
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only NT-proBNP was an independent predictor of NYHA
class≥3. GDF15 was of borderline significance. After NT-
proBNPwas added to the model, age and PAHwere no longer
independent predictors of NYHA class≥3 (Table 3).
Discussion
This study demonstrates that both new and established bio-
markers are correlated only weakly with clinical signs and
Table 2 Spearman correlations (ρ) between biomarkers and clinical signs and symptoms (ρ)
Baseline Visit 1 month Visit 3 months Visit 6 months Visit 12 months Visit 18 months
NT-proBNP
NYHA 0.22** 0.26** 0.28** 0.23** 0.32** 0.33**
Oedema 0.17** 0.18** 0.18** 0.18** 0.21** 0.20**
Rales 0.17** 0.16** 0.09 0.18** 0.17** 0.22**
JVD 0.23** 0.28** 0.25** 0.27** 0.29** 0.37**
Orthopnoea 0.13** 0.23** 0.23** 0.28** 0.24** 0.22**
Cystatin-C
NYHA 0.21** 0.22** 0.25** 0.20** 0.20** 0.34**
Oedema 0.15** 0.21** 0.22** 0.17** 0.18** 0.23**
Rales 0.10* 0.09 0.10* 0.16** 0.10 0.16**
Jugular vein 0.12** 0.20** 0.23** 0.11* 0.22** 0.24**
Orthopnoea 0.15** 0.18** 0.20** 0.20** 0.23** 0.23**
hsTNT
NYHA 0.22** 0.23** 0.25** 0.21** 0.27** 0.33**
Oedema 0.07 0.20** 0.18** 0.19** 0.22** 0.21**
Rales 0.17** 0.15** 0.12** 0.14** 0.19** 0.13*
JVD 0.19** 0.18** 0.24** 0.22** 0.28** 0.25**
Orthopnoea 0.18** 0.19** 0.19** 0.24** 0.29** 0.15**
hsCRP
NYHA 0.14** 0.19** 0.16** 0.07 0.12* 0.12*
Oedema 0.18** 0.19** 0.12* 0.19** 0.15** 0.19**
Rales 0.19** 0.18** 0.08 0.02 0.03 0.17**
JVD 0.13** 0.15** 0.15** 0.10* 0.10* 0.02
Orthopnoea 0.13** 0.18** 0.13** 0.11* 0.22** 0.11*
GDF15
NYHA 0.24** 0.22** 0.26** 0.23** 0.29** 0.31**
oedema 0.18** 0.22** 0.19** 0.16** 0.18** 0.15**
Rales 0.14** 0.12** 0.12** 0.16** 0.15** 0.16**
JVD 0.30** 0.28** 0.32** 0.19** 0.29** 0.32**
Orthopnoea 0.17** 0.17** 0.23** 0.22** 0.25** 0.24**
*p <0.05, **P<0.01. JVD jugular vein distention
Fig. 1 Spearman’s correlation
(ρ) between NT-proBNP and
NYHA divided by treatment
group in all patients (a), early-
included patients (b) and late-
included patients (c); NT-proBNP
guided (black), clinically guided
(grey) *=P<0.05; **=P <0.001,
***=P<0.0001
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symptoms of HF, that clinical signs and symptoms are influ-
enced by several comorbidities and patient characteristics
independent of HF and that the use of biomarkers may influ-
ence clinical judgement.
HF has a highly complex, multi-organ pathophysiology.
Correlations between clinical signs as well as symptoms and
biomarkers reflecting these pathophysiological mechanisms
were found to be weak. This may have various reasons. For
instance, serum levels of biomarkers as NT-proBNP respond
rapidly to changes in disease severity [25] and have short half-
times [26], whereas clinical signs and symptoms may be less
sensitive due to systemic compensatory reactions [27]. Also,
patient characteristics and diseases other than HF may signif-
icantly influence the severity of symptoms. Indeed, NYHA
classification was found to be influenced by comorbidities and
patient characteristics such as anaemia, PAH, presence of
multiple comorbidities as well as age, BMI and gender. Still,
some patient characteristics and comorbidities may influence
biomarkers and symptoms likewise and not independently of
each other. Also COPD, which logically should have a nega-
tive effect on NYHA classification, was not identified as a
significant predictor of low functionality in our study. These
findings highlight the complexity of the clinical assessment
and the fact that none of the signs and symptoms are really
specific for HF.
Finally, clinical assessment is subjective and therefore has
important limitations. NYHA classification has large inter-
observer variability, resulting in the finding that classification
of patients in class II or III may depend on little more than
chance [28]. Other clinical symptoms have hardly been stud-
ied with respect to their accuracy and reproducibility. Howev-
er, previous studies in acute decompensated HF showed their
limitation for correct clinical assessment and more objective
tests including measurements of BNP and NT-proBNP may
be more accurate [29]. Our findings are in agreement with
these results, as we showed that biomarkers do not merely
reflect signs or symptoms of HF and may thus provide addi-
tional information. This suggests that biomarkers may add to
clinical judgement in HF patients in clinically stable
condition.
A number of studies, in agreement with our results, have
reported significant associations between natriuretic peptides
Table 3 Univariate and multivariate logistic regression on the association of patient characteristics, comorbidities and biomarkers, with a low functional
class NYHA ≥3
Univariate Patient characteristics Characteristics and biomarkers
OR 95 % C.I P OR 95 % C.I P OR 95 % C.I P
Biomarkers
BNP-lg10 3.70 2.21 – 6.18 <0.0001 3.15 1.59 – 6.24 0.001
Cystatin-C 2.35 1.56 – 3.55 <0.0001
hsCRP-lg10 1.58 1.14 – 2.20 0.006
hsTnT-lg10 2.27 1.14 – 3.66 0.001
GDF15-lg10 7.49 3.14 – 17.83 <0.0001 2.84 0.95 – 8.46 0.061
Characteristics
Female 2.05 1.37 – 3.06 <0.0001 1.86 1.21 – 2.85 0.005 1.83 1.11 – 3.00 0.017
Age 1.05 1.02 – 1.08 <0.0001 1.04 1.02 – 1.07 0.002 1.03 1.00 – 1.06 0.098
BMI 0.058 0.009 0.018
BMI <20 0.35 0.16 – 0.77 0.009 0.24 0.10 – 0.54 0.001 0.21 0.08 – 0.55 0.002
BMI 20–25 0.63 0.34 – 1.16 0.138 0.54 0.28 – 1.02 0.056 0.52 0.26 – 1.06 0.071
BMI 25–30 0.54 0.29 – 0.99 0.048 0.53 0.28 – 1.01 0.053 0.60 0.29 – 1.21 0.153
Syst. dysfunction 0.60 0.39 – 1.00 0.048
Comorbidities
COPD 1.27 0.93 – 1.73 0.131
Stroke 0.94 0.49 – 1.81 0.854
Kidney disease 1.43 0.99 – 2.07 0.057
PAHT 3.03 1.18 – 7.78 0.021 2.73 1.04 – 7.15 0.041 2.70 0.91 – 8.00 0.074
Anaemia 2.06 1.30 – 3.26 0.002 1.98 1.23 – 3.19 0.005 1.53 0.88 – 2.65 0.129
Cancer 1.13 0.65 – 1.95 0.663
>2 comorbidities 1.54 1.03 – 2.31 0.034
PAOD 0.88 0.56 – 1.39 0.589
BMI body mass index; COPD chronic obstructive pulmonary disease; PAHT pulmonary artery hypertension, PAOD peripheral artery occlusive disease
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and NYHA classification [14–21]. However, only two studies
were identified that reported the specific correlations between
NT-proBNP and NYHA classification. Those reported stron-
ger correlations than we identified [18, 19]. This disagreement
may have several reasons. Population sizes were significantly
smaller than in our study [18, 19]. Also, population charac-
teristics were different, the patients being younger and having
lower NYHA classification scores [18, 19]. We found that
correlations between NYHA class and NT-proBNP were
weaker with increasing age. None of these studies reported
extensively on comorbidities [18, 19] and one did not report
BMI index [19], which may have influenced NYHA classifi-
cation. In the latter study, patients also did not have an objec-
tive proof of HF [19], nor was it reported whether NT-proBNP
measurements were blinded for investigators performing
NYHA classification [19], which may have influenced their
clinical judgement as suggested by our results.
As the study progressed, correlations between NT-proBNP
and NYHA class became significantly stronger in the NT-
proBNP-guided, but not the symptom-guided group, where
investigators were blinded to the NT-proBNP results. This
strongly suggests that clinical judgement may be influenced
by knowledge of NT-proBNP results. Interestingly, the differ-
ence in correlation is even more pronounced in late-included
patients, while in early-included patients this relationship is
virtually absent. Therefore, it seems that clinicians become
more influenced in their clinical judgement by knowledge of
biomarker concentrations, as they become more familiar with
their interpretation. The correlation between other biomarkers
and NYHA class were not influenced by study duration.
These were not used in clinical management and investigators
were blinded to them in both treatment groups. The relation-
ship was also far less with other signs and symptoms of HF.
This might be explained, as assessment of oedema and espe-
cially rales, jugular vein distention and orthopnoea may be
less vulnerable to subjective interpretation of clinicians. How-
ever, this assumption was not properly tested and should be
investigated prospectively.
As this study is a post-hoc analysis, it inevitably has lim-
itations and should be valued as exploratory. Also investiga-
tors participating in the trial may be more accustomed to using
biomarkers in their clinical practice. However, if this assump-
tion were true, it would further reduce the already weak
correlation found.
In conclusion, biomarkers including NT-proBNP were on-
ly weakly correlated to signs and symptoms. At first glance,
this might seem controversial and could raise questions re-
garding the importance of biomarkers in HF management.
However, our findings may actually support the utility of
biomarkers in the clinical setting, as they may provide addi-
tional information rather than merely reflecting signs and
symptoms and confirm what is already known. Importantly,
our data suggest that knowledge of biomarkers may
significantly influence clinical judgement, which may have
important implications regarding the use of biomarkers in
clinical practice.
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